ExosomeDx Webinars & Urology Resources

Prostate cancer guidelines seek to optimize diagnosis while minimizing over-diagnosis. This webinar explores integrating biomarkers like ExoDx Prostate Test with MRI imaging for better risk assessment in patients considering biopsy.

In this episode of BackTable Urology, Dr. Jose Silva interviews Dr. Ali Kasraeian, a private practice urologic oncologist in Jacksonville, about different techniques and research on prostate cancer screenings.

Dr. Geo interviewed Dr. Jason Alter, the Head of Scientific Affairs at Exosome Diagnostics, regarding the effectiveness of urine tests for identifying prostate cancer.

Part 3 of 3. Dr. Phranq Tamburri, N.M.D., presents on what makes the ExoDx Prostate Test unique as well as why liquid biomarkers are useful.

Part 2 of 3. Dr. Phranq Tamburri, N.M.D., explains more about PSA (Prostate Specific Antigen) and three factors in assessing prostate cancer.

Dr. Phranq Tamburri, N.M.D., presents on pandemic-induced changes in prostate cancer screening, the significance of PSA assessment amidst evolving guidelines, and the benefits of analyzing 3 genes in the ExoDx Prostate Test.

Dr. Alexander Kretschmer, and colleagues demonstrated utility of the ExoDx™ Prostate test, to address limitations related to prostate biopsy sampling error, prostate biopsy bias as well as multifocality of of the disease, providing a more relevant assessment of low-risk men who could remain on AS.

In this webinar, Dr. John Smith and Dr. Albala explore the breakthrough ExoDx™ Prostate Test, a non-invasive risk assessment tool for prostate cancer. They discuss its accuracy and ability to guide treatment decisions, highlighting its potential to revolutionize prostate cancer management.

Join Dr. Kasraeian for this discussion on the “5 W’s” of Liquid Biopsy approaches, including Who, What, Why Where, and When to use liquid biopsy testing to improve management of prostate cancer.